LATS1
MOLECULAR TARGETlarge tumor suppressor kinase 1
LATS1 (large tumor suppressor kinase 1) is targeted by 30 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting LATS1
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | ibrutinib | 4.86 | 128 |
| 2 | tozasertib | 4.33 | 75 |
| 3 | midostaurin | 3.85 | 46 |
| 4 | fasudil | 3.66 | 38 |
| 5 | nintedanib | 3.61 | 36 |
| 6 | tae 684 | 3.43 | 30 |
| 7 | gilteritinib | 3.40 | 29 |
| 8 | linifanib | 3.33 | 27 |
| 9 | dovitinib | 3.09 | 21 |
| 10 | at 9283 | 3.09 | 21 |
| 11 | lestaurtinib | 3.04 | 20 |
| 12 | pf 03758309 | 3.00 | 19 |
| 13 | ruboxistaurin | 2.94 | 18 |
| 14 | orantinib | 2.89 | 17 |
| 15 | k 252a | 2.83 | 16 |
| 16 | milciclib | 2.77 | 15 |
| 17 | capivasertib | 2.77 | 15 |
| 18 | crenolanib | 2.71 | 14 |
| 19 | kw 2449 | 2.64 | 13 |
| 20 | gsk 690693 | 2.64 | 13 |
| 21 | linsitinib | 2.64 | 13 |
| 22 | ast 487 | 2.56 | 12 |
| 23 | defactinib | 2.48 | 11 |
| 24 | su 014813 | 2.20 | 8 |
| 25 | cyc 116 | 2.08 | 7 |
| 26 | tg100 115 | 2.08 | 7 |
| 27 | fostamatinib | 2.08 | 7 |
| 28 | uprosertib | 1.95 | 6 |
| 29 | pf 03814735 | 1.79 | 5 |
| 30 | hydroxyfasudil [Supplementary Concept] | 0.69 | 1 |
About LATS1 as a Drug Target
LATS1 (large tumor suppressor kinase 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 30 compounds with documented LATS1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
LATS1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.